



Erlotinib

Updated: June 28, 2018.

OVERVIEW

Introduction

Erlotinib is a tyrosine kinase receptor inhibitor that is used in the therapy of advanced or metastatic pancreatic or non-small cell lung cancer. Erlotinib therapy is associated with transient elevations in serum aminotransferase levels during therapy and rare instances of clinically apparent acute liver injury.

Background

Erlotinib (er loe' ti nib) is a selective inhibitor of several tyrosine kinase receptors which are associated with tumor growth and angiogenesis. The tyrosine kinase receptors are often mutated and over expressed in tumor tissue and cause unregulated cell growth and proliferation. Erlotinib is one of several tyrosine kinase inhibitors that have been introduced into cancer chemotherapy and are specially directed at molecular abnormalities that occur in cancer cells. Inhibition of the receptor can lead to reversal of progression of the cancer, although clinical responses are sometimes limited by the development of tumor resistance caused by further mutations in the receptor gene. Erlotinib has special activity against the human epidermal growth factor (EGF) tyrosine kinase receptors HER-1 and EGFR which are found in several forms of cancer. Erlotinib received approval for use in the United States in 2004. Current indications are for locally advanced, unresectable or metastatic pancreatic cancer in combination with gemcitabine and for locally advanced or metastatic non-small-cell lung cancer as a first line treatment in patients with specific, erlotinib sensitive mutations in EGFR or after failure of at least one chemotherapy regimen. Erlotinib is available in tablets of 25, 100 and 150 mg under the brand name Tarceva, and the typical dose is either 100 mg (pancreatic cancer) or 150 mg (lung cancer) once daily by mouth, continued until disease progresses or intolerable toxicity occurs. Side effects include fatigue, rash, diarrhea, anorexia, skin discoloration, hand-foot syndrome, edema, muscle cramps, arthralgias, headache, abdominal discomfort, anemia, cough, and pruritus. Uncommon, but potentially severe side effects include heart failure, interstitial lung disease, gastrointestinal perforation, pancreatitis, renal failure, severe skin reactions and embryo-fetal toxicity.

Hepatotoxicity

Elevations in serum aminotransferase levels are common during erlotinib therapy of pancreatic and lung cancers, and values above 5 times the upper limit of normal occur in at least 10% of patients. Similar rates of ALT elevations, however, can occur with comparable antineoplastic regimens. The abnormalities are usually asymptomatic and self-limited, but may require dose adjustment or discontinuation (Case 1). In addition, there have been rare reports of clinically apparent liver injury attributed to erlotinib therapy. The time to onset is typically within days or weeks of starting therapy, and the liver injury can be severe, there being at least a dozen

fatal instances reported in the literature. The onset of injury can be abrupt and the pattern of serum enzyme elevations is usually hepatocellular (Case 2). Immunoallergic features (rash, fever and eosinophilia) are not common and autoantibody formation has not been reported. Routine monitoring of liver tests during therapy is recommended. The rate of clinically significant liver injury and hepatic failure is increased in patients with preexisting cirrhosis or hepatic impairment due to liver tumor burden.

Likelihood score: B (likely but uncommon cause of clinically apparent liver injury).

Mechanism of Injury

The abrupt and severe nature of the clinically apparent liver injury attributed to erlotinib suggests that it is immunologically mediated. In contrast, the transient serum enzyme elevations that occur during therapy may have a different cause and be the result of direct toxicity. Erlotinib is metabolized in the liver through the cytochrome P450 system (largely CYP 3A4).

Outcome and Management

Liver injury due to erlotinib varies in severity from minor, transient serum enzyme elevations to acute symptomatic hepatitis and acute liver failure. Monitoring of routine liver tests before starting and at regular intervals during erlotinib therapy is recommended. Serum aminotransferase elevations above 5 times the upper limit of normal (if confirmed) should lead to temporary discontinuation, which should be permanent if laboratory values do not improve significantly or resolve within 3 weeks. Restarting therapy is usually, but not always followed by recurrence of the serum enzyme elevations. There appears to be partial cross sensitivity to liver injury among similar tyrosine kinase receptor inhibitors and, in some situations, switching to another with careful monitoring may be appropriate. Cases of acute liver failure have occurred in patients receiving erlotinib and are challenging as these patients rarely qualify for liver transplantation. Patients with acute liver failure due to erlotinib have been treated with corticosteroids, but their benefit remains unproven. In using this medication, other potentially hepatotoxic agents should be avoided (such as high doses of acetaminophen).

Drug Class: Antineoplastic Agents, Protein Kinase Inhibitors

CASE REPORTS

Case 1. Serum enzyme elevations due to erlotinib therapy.

[Modified from: Saif MW. Erlotinib-induced acute hepatitis in a patient with pancreatic cancer. *Clin Adv Hematol Oncol* 2008; 6: 191-9. [PubMed Citation](#)]

A 52 year old man with locally advanced pancreatic cancer developed rising serum enzyme elevations 7 weeks after starting erlotinib therapy. He had presented initially with jaundice and was found to have a mass in the head of the pancreas that was shown to be adenocarcinoma by thin needle aspiration. He was treated initially with biliary stenting followed by gemcitabine, oxaliplatin and external beam radiation. Because of unresectability and oxaliplatin induced neuropathy, he was then treated with gemcitabine and erlotinib. His baseline liver tests were mildly abnormal and he was monitored carefully during erlotinib therapy. Seven weeks after starting erlotinib, serum ALT and alkaline phosphatase levels began to rise (Table). He was maintained on erlotinib and gemcitabine and monitored more carefully. Eleven weeks into treatment, however, serum enzymes had risen to more than 5 times the upper limit of the normal range. Tests for hepatitis A, B and C were negative and he was taking no other medications. Abdominal imaging showed no interval change in the pancreatic mass and no evidence of extrahepatic obstruction. Erlotinib was stopped and he was maintained on gemcitabine alone. Liver enzymes decreased to baseline values within the following 8 weeks.

Key Points

Medication:	Erlotinib (100 mg daily)
Pattern:	Cholestatic (R=1.9)
Severity:	1+ (serum enzyme elevations only)
Latency:	7-13 weeks
Recovery:	8 weeks
Other medications:	Gemcitabine

Laboratory Values

Time After Starting	Time After Stopping	ALT (U/L)	Alk P (U/L)	Bilirubin (mg/dL)	Other
- 6 months		39	85	0.5	
0		53	176	0.5	Erlotinib started
4 weeks		41	144	0.3	
6 weeks		76	145	0.5	
9 weeks		70	162	0.4	CT scan: no change
11 weeks		131	283	0.3	
13 weeks	0	193	376	0.7	Erlotinib stopped
14 weeks	1 weeks	199	346	0.3	
15 weeks	2 weeks	288	491	0.4	
16 weeks	3 weeks	157	444	0.2	
19 weeks	6 weeks	85	259	0.3	
22 weeks	9 weeks	62	176	0.4	
Normal Values		<35	<130	<1.2	

Comment

The patient developed gradual increases in serum aminotransferase and alkaline phosphatase levels while being treated with erlotinib, and therapy was discontinued when ALT levels reached 5 times the upper limit of the normal range (considered Grade 3 toxicity). The severity of the liver injury, however, should be considered mild, as there was no jaundice and apparently no symptoms of hepatic injury. Because the patient had pancreatic cancer, the abnormalities could have indicated progressive malignant disease, particularly because of the cholestatic pattern of the enzymes and their gradual rise. However, imaging showed no evidence of an increase in the size of the pancreatic mass or evidence of biliary obstruction, and the abnormalities resolved once erlotinib was stopped. Grade 3 elevations in serum ALT levels occur in 5% to 10% of patients treated with erlotinib and gemcitabine, and this rate is only slightly higher than occurs with gemcitabine alone.

Case 2. Acute liver failure and death due to erlotinib therapy.

[Modified from: Liu W, Makrauer FL, Qamar AA, Jänne PA, Odze RD. Fulminant hepatic failure secondary to erlotinib. Clin Gastroenterol Hepatol 2007; 5: 917-20. [PubMed Citation](#)]

A 57 year old woman with metastatic non-small cell lung cancer and mutation of the EGFR gene in tumor tissue was treated with erlotinib (150 mg daily) and developed an acne-form skin rash 2 weeks later. The rash worsened and laboratory tests showed mild elevations in serum enzymes (ALT 80 U/L with normal AST and serum bilirubin). Because of the rash and stomatitis, erlotinib was stopped. The rash and mouth ulcers resolved rapidly

and 2 weeks later erlotinib was restarted; however, 10 days later she developed anorexia and jaundice. She denied fever, chills, rash or abdominal pain. She had no history of liver disease, was not taking other medications, had no risk factors for viral hepatitis and was known to have had normal liver tests in the past (Table). On examination, she was jaundiced and appeared chronically ill. Laboratory tests showed a serum bilirubin of 13.6 mg/dL with marked elevations in serum ALT [2021 U/L] and AST [1476 U/L] and minor elevations in alkaline phosphatase [304 U/L]. Erlotinib was discontinued and she was admitted for management. Liver ultrasound and computerized tomography showed a small amount of ascites, but no evidence of hepatic masses or extrahepatic obstruction. A liver biopsy showed submassive hepatic necrosis with marked portal inflammation and ductular proliferation. Tests for hepatitis A, B and C and Epstein Barr virus infection were negative as were routine autoantibodies. Over the next few days, she experienced worsening jaundice, further prolongation of prothrombin time, hepatic encephalopathy and hepatorenal syndrome, and died on the 11th hospital day. Autopsy was refused.

Key Points

Medication:	Erlotinib (100 mg daily)
Pattern:	Hepatocellular (R=15)
Severity:	5+ (acute liver failure and death)
Latency:	11 days after restarting
Recovery:	None
Other medications:	Budesonide nasal spray and flunisolide inhaler

Laboratory Values

Time After Starting	Time After Stopping	ALT (U/L)	Alk P (U/L)	Bilirubin (mg/dL)	Other
- 3 months	Pre	19	89	0.6	
0	0	30	99	0.5	Erlotinib started
2 weeks	0	82	119	0.6	Skin rash
4 weeks	0	57	69	1.9	Erlotinib stopped
Erlotinib restarted 2 weeks after discontinuation, and 1 week after resolution of rash					
11 days	0	2021	304	13.6	INR=2.0, Erlotinib stopped
14 days	2 days	2037	174	18.1	Liver biopsy
17 days	5 days	857	137	24.1	INR=3.4
22 days	10 days	437	145	28.4	INR=9.0, creatinine 5.0 mg/dL
23 days	11 days	Patient died of multiorgan failure			
Normal Values		<52	<118	<1.2	

Comment

Several instances of acute liver failure have been reported in patients treated with erlotinib for non-small cell lung cancer. The onset was abrupt, within days of starting or restarting therapy. The liver disease was rapidly progressive with coagulopathy, hepatic encephalopathy, renal insufficiency and death from multiorgan failure within 1 to 2 weeks of presentation, despite prompt discontinuation of the erlotinib. Liver histology in this case demonstrated a severe acute hepatitis with submassive necrosis. The cause of the injury is unknown, but the rapidity of onset suggests immune factors. Cases of acute hepatitis and acute liver failure were not reported in

the preregistration clinical trials of erlotinib that included several thousand patients. Thus, hepatic failure is rare and most likely to occur with rechallenge or if serum enzyme levels are not being monitored.

PRODUCT INFORMATION

REPRESENTATIVE TRADE NAMES

Erlotinib – Tarceva®


DRUG CLASS

Antineoplastic Agents

COMPLETE LABELING

Product labeling at DailyMed, National Library of Medicine, NIH

CHEMICAL FORMULA AND STRUCTURE

DRUG	CAS REGISTRY NUMBER	MOLECULAR FORMULA	STRUCTURE
Erlotinib	183321-74-6	C ₂₂ H ₂₃ N ₃ O ₄	 The chemical structure of Erlotinib is shown. It features a central benzimidazole ring system. The benzimidazole ring is substituted with a 2-methoxyethoxy group and a 2-(2-methoxyethyl)oxy group on the benzene ring, and a 4-ethynylphenyl group on the imidazole ring.

ANNOTATED BIBLIOGRAPHY

References updated: 28 June 2018

Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999.

(Review of hepatotoxicity published in 1999 before the availability of tyrosine kinase receptor inhibitors).

DeLeve LD. Erlotinib. Cancer chemotherapy. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 556.

(Review of hepatotoxicity of cancer chemotherapeutic agents published mentions that erlotinib has been linked to several cases of clinically apparent liver injury, 2 of which were fatal).

Chabner BA, Barnes J, Neal J, Olson E, Mujagic H, Sequist L, Wilson W, et al. Targeted therapies: tyrosine kinase inhibitors, monoclonal antibodies, and cytokines. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1731-54.

(Textbook of pharmacology and therapeutics).

- Moore MJ, Goldstein D, Hamm J, Figier A, Hecht JR, Gallinger S, Au HJ, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. *J Clin Oncol* 2007; 25: 1960-6. PubMed PMID: 17452677.
- (Among 569 patients with advanced pancreatic cancer randomized to receive gemcitabine alone vs its combination with erlotinib, AST elevations above 5 times ULN occurred in 11% on the combination vs 8% on gemcitabine alone).*
- Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. *N Engl J Med* 2005; 353: 123-32. PubMed PMID: 16014882.
- (Among 731 previously treated patients with non-small cell lung cancer treated with erlotinib or placebo, 5% stopped therapy because of side effects, but none because of hepatotoxicity; rates of ALT elevations not mentioned).*
- Ramanarayanan J, Scarpace SL. Acute drug induced hepatitis due to erlotinib. *JOP* 2007; 8: 39-43. PubMed PMID: 17228132.
- (70 year old man with metastatic pancreatic cancer developed ALT elevations 2 weeks after starting erlotinib [ALT peak 580 U/L, Alk P 618 U/L], the ALT levels falling upon stopping therapy, but Alk P rising further).*
- Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, et al. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. *J Clin Oncol* 2007; 25: 4787-92. PubMed PMID: 17947726.
- (30 patients with refractory metastatic pancreatic cancer were treated with capecitabine and erlotinib; mild AST elevations occurred in 2 patients [7%]).*
- Liu W, Makrauer FL, Qamar AA, Jänne PA, Odze RD. Fulminant hepatic failure secondary to erlotinib. *Clin Gastroenterol Hepatol* 2007; 5: 917-20. PubMed PMID: 17625975.
- (67 year old woman with non-small cell lung cancer developed mild ALT elevations and rash 4 weeks after starting erlotinib which resolved upon stopping, but 10 days after restarting she became jaundiced [bilirubin 13.6 mg/dL, ALT 2021 U/L, Alk P 304 U/L] and developed hepatic failure and died 11 days later: Case 2).*
- Thomas MB, Chadha R, Glover K, Wang X, Morris J, Brown T, Rashid A, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. *Cancer* 2007; 110: 1059-67. PubMed PMID: 17623837.
- (40 patients with unresectable hepatocellular carcinoma were treated with 1 to 16 28-day courses of erlotinib; AST elevations occurred in 7 patients [18%], but were above 5 times ULN in only 1 [2.5%]).*
- Saif MW. Erlotinib-induced acute hepatitis in a patient with pancreatic cancer. *Clin Adv Hematol Oncol* 2008; 6: 191-9. PubMed PMID: 18391918.
- (52 year old man with advanced pancreatic cancer developed rising levels of ALT and Alk P 7 weeks after starting erlotinib, with peak levels at week 10 [bilirubin 0.7 mg/dL, ALT 193 U/L, Alk P 376 U/L], which fell to baseline two months after stopping: Case 1).*
- Saif MW. Hepatic failure and hepatorenal syndrome secondary to erlotinib. Safety reminder. *JOP* 2008; 9: 748-52. PubMed PMID: 18981559.
- (Review of the hepatotoxicity of erlotinib and its use in patients with preexisting liver dysfunction).*
- Ramanarayanan J, Krishnan GS. Review: hepatotoxicity and EGFR inhibition. *Clin Adv Hematol Oncol* 2008; 6: 200-1. PubMed PMID: 18391919.
- (Review of hepatotoxicity of EGF receptor tyrosine kinase inhibitors focusing upon erlotinib and gefitinib).*

- Pellegrinotti M, Fimognari FL, Franco A, Repetto L, Pastorelli R. Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer. *Ann Pharmacother* 2009; 43: 542-5. PubMed PMID: 19261961.
- (77 year old man with non-small cell lung cancer developed shortness of breath and delirium 12 days after starting erlotinib [bilirubin 1.0 mg/dL, ALT 1299 U/L, LDH 5990 U/L, creatinine 4.4 mg/dL], with lactic acidosis [pH 7.1] and rapid demise within hours of presentation).*
- Huang YS, An SJ, Chen ZH, Wu YL. Three cases of severe hepatic impairment caused by erlotinib. *Br J Clin Pharmacol* 2009; 68: 464-7. PubMed PMID: 19740406.
- (Three men, ages 31, 58 and 72 years, with non-small cell lung cancer developed hepatotoxicity after 2 to 7 days of erlotinib therapy [bilirubin 1.4, 6.7 and 0.9 mg/dL, ALT 896, 745 and 1412 U/L, Alk P not given], all dying of hepatic failure within 2-14 days of presentation).*
- Erlotinib: potentially fatal in cases of liver failure: a contraindication. *Prescrire Int* 2009; 18: 167. PubMed PMID: 19746532.
- (Short discussion of report of 15 cases of liver failure in patients taking erlotinib, many had preexisting liver involvement due to cancer).*
- Schacher-Kaufmann S, Pless M. Acute Fatal Liver Toxicity under Erlotinib. *Case Rep Oncol* 2010; 3: 182-8. PubMed PMID: 20740194.
- (53 year old with non-small cell lung cancer developed anorexia within 9 days, abdominal pain and fever after 17 days at which point erlotinib was stopped, but she then developed jaundice [bilirubin 4.7 mg/dL, ALT 884 U/L, Alk P 814 U/L] and progressive liver failure with thrombotic microangiopathy, dying 2 weeks after stopping erlotinib).*
- Steins M, Thomas M, Geissler M. Erlotinib. *Recent Results Cancer Res* 2010; 184: 21-31. PubMed PMID: 20072828.
- (Review of development, mechanism of action, efficacy and safety of erlotinib in pancreatic, liver and non-small cell lung cancer; class specific adverse effects of EGFR inhibitors include xerosis, acneiform eruptions, eczema and diarrhea; rarely these agents cause interstitial lung disease and hepatotoxicity).*
- Ohashi Y, Suzuki K, Sakurai M, Ishikawa H, Onishi T, Nakagaki S, Kato T, et al. [Safety analysis of eight patients treated with erlotinib after severe gefitinib-induced liver injury]. *Gan To Kagaku Ryoho* 2010; 37: 1307-11. Japanese. PubMed PMID: 20647715.
- (Abstract only: only one of 8 patients with severe gefitinib hepatotoxicity developed liver injury when switched to erlotinib, whereas the liver injury usually recurred upon restarting gefitinib, even at lower doses).*
- Takeda M, Okamoto I, Fukuoka M, Nakagawa K. Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity. *J Clin Oncol* 2010; 28: e273-4. PubMed PMID: 20385983.
- (66 year old woman with lung cancer developed ALT elevations after 36 weeks of treatment with gefitinib [ALT peak ~1011 U/L], resolving within 8 weeks of stopping and not recurring on starting erlotinib).*
- Kim ST, Lee J, Kim JH, Won YW, Sun JM, Yun J, Park YH, et al. Comparison of gefitinib versus erlotinib in patients with non-small cell lung cancer who failed previous chemotherapy. *Cancer* 2010; 116: 3025-33. PubMed PMID: 20564408.
- (Retrospective analysis of 467 patients with non-small cell lung cancer treated with either gefitinib or erlotinib found similar rates of clinical response; no discussion of adverse events).*
- Ku GY, Chopra A, de Lima Lopes G Jr. Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity. *Lung Cancer* 2010; 70: 223-5. PubMed PMID: 20817304.

- (Two men, ages 52 and 88 years, with non-small cell lung cancer developed serum ALT elevations 4 and 6 weeks after starting gefitinib [bilirubin normal, peak ALT 354 and 297 U/L], resolving rapidly on stopping and not recurring when switched to erlotinib).*
- Gunturu KS, Abu-Khalaf M, Saif MW. Hepatic failure and hepatorenal syndrome secondary to erlotinib: a possible etiology of complications in a patient with pancreatic cancer. *JOP* 2010; 11: 484-5. PubMed PMID: 20818124.
- (39 year old man with advanced pancreatic cancer developed weakness and rash after 3 days of erlotinib therapy [bilirubin 4.0 rising to 17.2 mg/dL, ALT 489 U/L], rapidly progressing to liver failure associated with diffuse liver metastases and malignant ascites).*
- Nakatomi K, Nakamura Y, Tetsuya I, Kohno S. Treatment with gefitinib after erlotinib-induced liver injury: a case report. *J Med Case Reports* 2011; 5: 593. PubMed PMID: 22188652.
- (31 year old woman with metastatic lung cancer developed enzyme elevations 4 weeks after starting erlotinib [peak ALT 3130 U/L] that fell to normal within 3 weeks of stopping, and did not rise again when she was started on gefitinib).*
- Lai YC, Lin PC, Lai JI, Hsu SY, Kuo LC, Chang SC, Wang WS. Successful treatment of erlotinib-induced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review. *Int J Clin Pharmacol Ther* 2011; 49: 461-6. PubMed PMID: 21726497.
- (74 year old man developed interstitial pneumonitis and mild serum enzyme elevations 1 month after starting erlotinib [ALT 116 U/L], both of which improved within days on high dose corticosteroids).*
- Kijima T, Shimizu T, Nonen S, Furukawa M, Otani Y, Minami T, Takahashi R, et al. Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism. *J Clin Oncol* 2011; 29: e588-90. PubMed PMID: 21502555.
- (Two women, ages 67 and 83 years, with lung cancer developed elevated aminotransferase levels 4 and 8 weeks after starting gefitinib [peak ALT 731 and ~450 U/L, bilirubin and Alk P not given], which resolved upon stopping, recurred on restarting, but did not recur when erlotinib was used).*
- Kunimasa K, Yoshioka H, Iwasaku M, Nishiyama A, Korogi Y, Masuda G, Takaiwa T, et al. Successful treatment of non-small cell lung cancer with gefitinib after severe erlotinib-related hepatotoxicity. *Intern Med* 2012; 51: 431-4. PubMed PMID: 22333382.
- (64 year old woman with non-small cell lung cancer developed abnormal liver tests 5 weeks after starting erlotinib [bilirubin normal, ALT 129, Alk P 819 U/L], which improved on stopping, but recurred on restarting, but did not recur upon switching to gefitinib).*
- Yang ZY, Yuan JQ, Di MY, Zheng DY, Chen JZ, Ding H, Wu XY, et al. Gemcitabine plus erlotinib for advanced pancreatic cancer: a systematic review with meta-analysis. *PLoS One* 2013; 8: e57528. PubMed PMID: 23472089.
- (Review of literature on efficacy and safety of the combination of erlotinib and gemcitabine for advanced pancreatic cancer; the addition of erlotinib was associated with a prolongation of survival by 0.3 months and the adverse event rate was high "but not surprising"; no mention of hepatotoxicity).*
- Kitade H, Yamada T, Igarashi S, Hokkoku K, Mori M, Shintaku K, Sagawa M, et al. [Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations]. *Gan To Kagaku Ryoho* 2013; 40: 79-81. PubMed PMID: 23306923.
- (80 year old woman developed ALT elevations [3 times ULN] on gefitinib, which resolved on stopping and did not recur on erlotinib [for 3 years]).*

- Takimoto T, Kijima T, Otani Y, Nonen S, Namba Y, Mori M, Yokota S, et al. Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity. *Clin Lung Cancer* 2013; 14: 502-7. PubMed PMID: 23664723.
- (Distribution of polymorphisms of CYP 2D6 gene were similar in 55 patients who developed ALT elevations during gefitinib therapy as found in the general Japanese population; 17 patients were switched to erlotinib and did not have recurrence of injury).*
- Yoshida T, Yamada K, Azuma K, Kawahara A, Abe H, Hattori S, Yamashita F, et al. Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis. *Med Oncol* 2013; 30: 349. PubMed PMID: 23263831.
- (Comparison of side effects in 107 patients with non-small cell lung cancer treated with gefitinib and 35 with erlotinib found "liver dysfunction" more frequent with gefitinib than erlotinib [13% vs 6%], whereas overall adverse events leading to drug discontinuation were less common [13% vs 26%]).*
- Yonesaka K, Suzumura T, Tsukuda H, Hasegawa Y, Ozaki T, Sugiura T, Fukuoka M. Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity. *Anticancer Res* 2014; 34: 5211-5. PubMed PMID: 25202117.
- (Among 25 patients with advanced NSCLC treated with gefitinib, 7 developed ALT elevations above 5 times ULN, all of whom then tolerated erlotinib [for 1 month to several years] with no or only minor enzyme elevations).*
- Durand M, Logerot S, Fonrose X, Schir E. [Treatment with erlotinib after gefitinib induced hepatotoxicity: literature review and case report]. *Therapie* 2014; 69: 163-8. French. PubMed PMID: 24926635.
- (Patient with NSCLC developed marked ALT elevations on gefitinib therapy with positive rechallenge, who nevertheless subsequently tolerated erlotinib without recurrence: Abstract only).*
- Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. *Gastroenterology* 2015; 148: 1340-52.e7. PubMed PMID: 25754159.
- (Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 49 were attributed to antineoplastic agents [5.5%], 9 of which were attributed to kinase inhibitors [imatinib=5, lapatinib=2, regorafenib=1], but none to erlotinib).*
- Bui N, Wong-Sefidan I. Reactivation of hepatitis B virus after withdrawal of erlotinib. *Curr Oncol* 2015; 22: 430-2. PubMed PMID: 26715877.
- (62 year old woman with metastatic adenocarcinoma of the lung developed severe diarrhea and dehydration 4 weeks after starting erlotinib, which was stopped and one week later she was found to have de novo serum enzyme elevations [ALT 267, Alk P 448 U/L, bilirubin not given], at which time HBsAg was detectable without HBeAg in serum with HBV DNA level of 307 IU/mL; later tolerating restarting erlotinib while being treated for hepatitis B with entecavir).*
- Zenke Y, Umemura S, Sugiyama E, Kirita K, Matsumoto S, Yoh K, Niho S, et al. Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer. *Lung Cancer* 2016; 99: 1-3. PubMed PMID: 27565905.
- (57 year old man with NSCLC developed ALT elevations 7 weeks after starting gefitinib [bilirubin 2.0 mg/dL, ALT peak 594 U/L], which resolved upon stopping but he then developed worsening jaundice within a week of starting erlotinib [bilirubin 5.4 mg/dL, ALT normal], and he later tolerated afatinib; genetic testing revealed Gilbert syndrome and "poor metabolizer" phenotype of CYP 3A5).*
- Ueda H, Hayashi H, Kudo K, Takeda M, Nakagawa K. Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity. *Invest New Drugs* 2016; 34: 797-9. PubMed PMID: 27550238.

(67 year old woman with metastatic NSCLC developed ALT elevations 16 weeks after starting gefitinib [ALT 223 U/L] which improved upon stopping, recurred with restarting gefitinib and later recurred 10 weeks after starting erlotinib [ALT 262 U/L), which improved on stopping but recurred even with lower doses, but subsequent ALT levels remained normal on switching to afatinib).

Toba H, Sakiyama S, Takizawa H, Tangoku A. Safe and successful treatment with afatinib in three postoperative non-small cell lung cancer patients with recurrences following gefitinib/erlotinib-induced hepatotoxicity. *J Med Invest* 2016; 63 (1-2): 149-51. PubMed PMID: 27040072.

(Two women and one man, ages 63 to 73 years with NSCLC developed ALT elevations 4-8 weeks after starting gefitinib [which recurred in one 6 weeks after switching to erlotinib], but all three tolerated long term afatinib [7 months] without recurrence of enzyme elevations).

Bunchorntavakul C, Reddy KR. Drug hepatotoxicity: newer agents. *Clin Liver Dis* 2017; 21: 115-34. PubMed PMID: 27842767.

(Review of the hepatotoxicity of recently approved medications including the tyrosine kinase inhibitors and erlotinib which has been linked to serum enzyme elevations above 5 times ULN in 10-14% of patients and to individual cases of severe hepatotoxicity, some of which have been fatal).